Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Joseph D. Feuerstein, Kim L. Isaacs, Yecheskel Schneider, et al.
Gastroenterology (2020) Vol. 158, Iss. 5, pp. 1450-1461
Open Access | Times Cited: 556

Showing 1-25 of 556 citing articles:

Ulcerative colitis
Catherine Le Berre, Sailish Honap, Laurent Peyrin‐Biroulet
The Lancet (2023) Vol. 402, Iss. 10401, pp. 571-584
Closed Access | Times Cited: 579
Ulcerative Colitis in Adults
Beatriz Gros, Gilaad G. Kaplan
JAMA (2023) Vol. 330, Iss. 10, pp. 951-951
Closed Access | Times Cited: 253
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Daniel C. Baumgart, Catherine Le Berre
New England Journal of Medicine (2021) Vol. 385, Iss. 14, pp. 1302-1315
Closed Access | Times Cited: 243
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn, et al.
Gastroenterology (2021) Vol. 160, Iss. 7, pp. 2340-2353
Closed Access | Times Cited: 174
Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists
Manasi Agrawal, Elizabeth Spencer, Jean‐Frédéric Colombel, et al.
Gastroenterology (2021) Vol. 161, Iss. 1, pp. 47-65
Open Access | Times Cited: 164
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
María T. Abreu, David Rowbotham, Silvio Danese, et al.
Journal of Crohn s and Colitis (2022) Vol. 16, Iss. 8, pp. 1222-1234
Open Access | Times Cited: 83
Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response
Duaa Ahmed Elhag, Manoj Kumar, Marwa Saadaoui, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 6966-6966
Open Access | Times Cited: 76
Study of tumor necrosis factor receptor in the inflammatory bowel disease
Roberta Figueiroa Souza, Marcos Antônio Ferreira Caetano, Henrique Inhauser Riceti Magalhães, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 18, pp. 2733-2746
Open Access | Times Cited: 58
AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders
Edward L. Barnes, Manasi Agrawal, Gaurav Syal, et al.
Gastroenterology (2023) Vol. 166, Iss. 1, pp. 59-85
Open Access | Times Cited: 50
JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases
Claudia Herrera‐deGuise, X Serra-Ruiz, Ernesto Lastiri, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 47
Combination treatment of inflammatory bowel disease: Present status and future perspectives
John K. Triantafillidis, Constantinos G. Zografos, Manousos M. Konstadoulakis, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 15, pp. 2068-2080
Open Access | Times Cited: 19
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E. Sands, Geert R. D’Haens, David B. Clemow, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 12, pp. 2245-2258
Open Access | Times Cited: 17
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 5
Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery
Kat F. Kiilerich, Trine Andresen, Behrooz Darbani, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 575-575
Open Access | Times Cited: 2
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease
María José Temido, Sailish Honap, Vipul Jairath, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 2
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
Séverine Vermeire, Michael Chiorean, Julián Panés, et al.
Journal of Crohn s and Colitis (2021) Vol. 15, Iss. 6, pp. 950-959
Open Access | Times Cited: 75
Use of thiopurines in inflammatory bowel disease: an update
Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, et al.
Intestinal Research (2021) Vol. 20, Iss. 1, pp. 11-30
Open Access | Times Cited: 71
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis
Stefan D. Holubar, Amy L. Lightner, Vitaliy Poylin, et al.
Diseases of the Colon & Rectum (2021) Vol. 64, Iss. 7, pp. 783-804
Open Access | Times Cited: 61
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
Silvio Danese, Maria Kłopocka, Ellen Scherl, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 19, Iss. 11, pp. 2324-2332.e6
Open Access | Times Cited: 61
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Quazim A. Alayo, Marc Fenster, Osama Altayar, et al.
Crohn s & Colitis 360 (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 60
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Virginia Solitano, Antonio Facciorusso, Tine Jess, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 4, pp. 907-921.e2
Closed Access | Times Cited: 60
Cepharanthine ameliorates dextran sulphate sodium‐induced colitis through modulating gut microbiota
Honggang Wang, Minna Zhang, Xin Wen, et al.
Microbial Biotechnology (2022) Vol. 15, Iss. 8, pp. 2208-2222
Open Access | Times Cited: 56
Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases
Min‐Ji Kim, Jae‐Han Jeon
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2846-2846
Open Access | Times Cited: 52
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro–de Acosta, Irina Blumenstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 51
Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management
Viviana Laredo, Sandra G. García, Samuel J. Martínez‐Domínguez, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 871-871
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top